Research grant
CRI Clinical Innovator
Cancer Research Institute
- , Add deadline: choose a calendar
- Up to $1,000,000
- Worldwide
- Apply directly
- Oncology, Immunology and
About
Funding for investigator-initiated phase I/II or phase II cancer immunotherapy clinical trials designed and led by academic researchers. The programme emphasises novel immunotherapy approaches, mechanistic investigation of clinical response and the discovery or validation of predictive biomarkers, and favours studies that integrate standardised sample collection, correlative assays and advanced data analysis. Proposals on immunotherapy for chordoma can be co-funded with the Chordoma Foundation. An initial protocol concept is followed by an invited full proposal with the protocol.
Topics
- cancer immunotherapy, search World Wide
- clinical trials, search World Wide
- predictive biomarkers, search World Wide
- phase I/II, search World Wide
- phase II, search World Wide
- clinical response, search World Wide
- chordoma, search World Wide
- correlative assays, search World Wide
- advanced data analysis, search World Wide
Eligibility
Covers: Up to US$1 million per trial, paid against milestones, for investigator salary, patient costs, supplies, correlative assays and data analysis; indirect costs of up to 10% are provided in addition.
Medical schools or research centres in the United States or abroad; for-profit institutions are not supported.
Nationality or residence: No citizenship restrictions.
The applicant must be the principal investigator of the proposed study. There are no citizenship restrictions, and the research may be conducted at medical schools or research centres in the United States or abroad, but not at for-profit institutions. The initial protocol concept is due 1 December 2026; invited full proposals are due 1 April 2027.
Source: cancerresearch.org